STOCK TITAN

Cabaletta Bio to Participate in Upcoming Investor Conferences in March

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Cabaletta Bio, Inc. (Nasdaq: CABA), a biotechnology firm specializing in engineered T cell therapies for B cell-mediated autoimmune diseases, will participate in two investor conferences in March 2021. The first is the Cowen & Co. 41st Annual Health Care Conference on March 3, where CEO Steven Nichtberger will engage in a cell therapy panel. The second is the H.C. Wainwright Global Life Sciences Conference on March 9, featuring a pre-recorded fireside chat. The discussion will be available on-demand post-conference on the company’s website for 90 days.

Positive
  • None.
Negative
  • None.

PHILADELPHIA, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that the Company will participate in two upcoming investor conferences in March:

  • Cowen & Co. 41st Annual Health Care Conference on Wednesday, March 3, 2021: Steven Nichtberger, M.D., President and Chief Executive Officer, will participate in a cell therapy panel discussion beginning at 1:20 p.m. ET. Members of management will also be available for one-on-one meetings from Monday, March 1 to Thursday, March 4, 2021.

  • H.C. Wainwright Global Life Sciences Conference on Tuesday, March 9, 2021: Steven Nichtberger, M.D., President and Chief Executive Officer, will participate in a pre-recorded fireside chat, which will become available for on-demand viewing at 7:00 a.m. ET on Tuesday, March 9, 2021. Members of management will also be available for one-on-one meetings from Tuesday, March 9 to Wednesday, March 10, 2021.

The H.C. Wainwright pre-recorded fireside chat will be available for on-demand viewing on the News and Events section of the company’s website at www.cabalettabio.com. A replay of the pre-recorded fireside chat will be available on the website for 90 days.

About Cabaletta Bio
Cabaletta Bio is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. The Cabaletta Approach to selective B cell Ablation (CABA) platform, in combination with Cabaletta’s proprietary technology, utilizes Chimeric AutoAntibody Receptor (CAAR) T cells that are designed to selectively bind and eliminate only specific autoantibody-producing B cells while sparing normal antibody-producing B cells, which are essential for human health. The Company’s lead product candidate, DSG3-CAART, is being evaluated in the DesCAARTes™ phase 1 clinical trial as a potential treatment for patients with mucosal pemphigus vulgaris, a prototypical B cell-mediated autoimmune disease. The FDA granted Fast Track Designation for DSG3-CAART in May 2020. For more information about the clinical trial, please see www.clinicaltrials.gov. The Company’s lead preclinical product candidate, MuSK-CAART, is in IND-enabling studies and is designed as a potential treatment for patients with MuSK-associated myasthenia gravis. For more information, visit www.cabalettabio.com.

Contacts:
Anup Marda
Chief Financial Officer
investors@cabalettabio.com

Sarah McCabe
Stern Investor Relations, Inc.
212-362-1200
sarah.mccabe@sternir.com

 


FAQ

What investor conferences is Cabaletta Bio (CABA) attending in March 2021?

Cabaletta Bio will participate in the Cowen & Co. 41st Annual Health Care Conference on March 3, and the H.C. Wainwright Global Life Sciences Conference on March 9, 2021.

Who is representing Cabaletta Bio at the upcoming conferences?

Steven Nichtberger, M.D., the CEO, will represent Cabaletta Bio at both conferences.

When will the fireside chat from the H.C. Wainwright conference be available for viewing?

The fireside chat will be available for on-demand viewing at 7:00 a.m. ET on March 9, 2021.

What is the focus of Cabaletta Bio's therapies?

Cabaletta Bio focuses on engineered T cell therapies aimed at treating B cell-mediated autoimmune diseases.

What is the lead product candidate of Cabaletta Bio?

Cabaletta Bio's lead product candidate is DSG3-CAART, which is being evaluated for the treatment of mucosal pemphigus vulgaris.

Cabaletta Bio, Inc.

NASDAQ:CABA

CABA Rankings

CABA Latest News

CABA Stock Data

188.56M
48.85M
3.1%
105.81%
7.74%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
PHILADELPHIA